TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Smartphone Application for Smoking Cessation
Brief Summary: The purpose of this study is to test the effectiveness of a smartphone application for smoking cessation in smokers ages 18 to 65 years.


Options:
A: Arm Label: Video; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy | Arm Label: Voice; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Therapy | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): Video, Voice
B: Arm Label: Experimental App; Type: EXPERIMENTAL; Interventions: Behavioral: Experimental App | Arm Label: Active comparator app; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active Comparator App | Intervention Type: BEHAVIORAL; Name: Experimental App; Assigned to Arm(s): Experimental App | Intervention Type: BEHAVIORAL; Name: Active Comparator App; Assigned to Arm(s): Active comparator app
C: Arm Label: Information Prescription; Type: EXPERIMENTAL; Interventions: Behavioral: Smoking Coach | Arm Label: QUIT-PRIMO; Type: EXPERIMENTAL; Interventions: Behavioral: Decide2Quit | Intervention Type: BEHAVIORAL; Name: Decide2Quit; Assigned to Arm(s): QUIT-PRIMO | Intervention Type: BEHAVIORAL; Name: Smoking Coach; Assigned to Arm(s): Information Prescription
D: Arm Label: Standard Care; Type: OTHER; Interventions: Other: Standard Care | Arm Label: Extended Care Management; Type: EXPERIMENTAL; Interventions: Other: Extended Care Management | Intervention Type: OTHER; Name: Extended Care Management; Assigned to Arm(s): Extended Care Management | Intervention Type: OTHER; Name: Standard Care; Assigned to Arm(s): Standard Care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Smartphone Application for Smoking Cessation
Brief Summary: The purpose of this study is to test the effectiveness of a smartphone application for smoking cessation in smokers ages 18 to 65 years.


Options:
A: Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Behavioral: Mindful Eating | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mindful Eating; Assigned to Arm(s): Experimental
B: Arm Label: Stress reduction; Type: EXPERIMENTAL; Interventions: Behavioral: Transcendental Meditation | Arm Label: health education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Education | Intervention Type: BEHAVIORAL; Name: Transcendental Meditation; Assigned to Arm(s): Stress reduction | Intervention Type: BEHAVIORAL; Name: Health Education; Assigned to Arm(s): health education
C: Arm Label: MBCT; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness-Based Cognitive Therapy (MBCT) | Arm Label: CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy (CBT) | Arm Label: Waitlist; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mindfulness-Based Cognitive Therapy (MBCT); Assigned to Arm(s): MBCT | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy (CBT); Assigned to Arm(s): CBT
D: Arm Label: Experimental App; Type: EXPERIMENTAL; Interventions: Behavioral: Experimental App | Arm Label: Active comparator app; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active Comparator App | Intervention Type: BEHAVIORAL; Name: Experimental App; Assigned to Arm(s): Experimental App | Intervention Type: BEHAVIORAL; Name: Active Comparator App; Assigned to Arm(s): Active comparator app

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Smartphone Application for Smoking Cessation
Brief Summary: The purpose of this study is to test the effectiveness of a smartphone application for smoking cessation in smokers ages 18 to 65 years.


Options:
A: Arm Label: Experimental App; Type: EXPERIMENTAL; Interventions: Behavioral: Experimental App | Arm Label: Active comparator app; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active Comparator App | Intervention Type: BEHAVIORAL; Name: Experimental App; Assigned to Arm(s): Experimental App | Intervention Type: BEHAVIORAL; Name: Active Comparator App; Assigned to Arm(s): Active comparator app
B: Arm Label: Mindfulness Training for Smokers; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mindfulness Training for Smokers | Arm Label: Interactive Learning for Smokers; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Interactive Learning for Smokers | Intervention Type: BEHAVIORAL; Name: Mindfulness Training for Smokers; Assigned to Arm(s): Mindfulness Training for Smokers | Intervention Type: BEHAVIORAL; Name: Interactive Learning for Smokers; Assigned to Arm(s): Interactive Learning for Smokers
C: Arm Label: ACT; Type: EXPERIMENTAL; Interventions: Behavioral: ACT | Arm Label: CBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CBT | Intervention Type: BEHAVIORAL; Name: ACT; Assigned to Arm(s): ACT | Intervention Type: BEHAVIORAL; Name: CBT; Assigned to Arm(s): CBT
D: Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Behavioral: Smartphone-delivered Intervention (SmartQuit) | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: : Smartphone-delivered Intervention (Standard of care app) | Intervention Type: BEHAVIORAL; Name: Smartphone-delivered Intervention (SmartQuit); Assigned to Arm(s): Experimental | Intervention Type: BEHAVIORAL; Name: : Smartphone-delivered Intervention (Standard of care app); Assigned to Arm(s): Control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sucrose Practices for Pain in Neonates: A Program of Research: Part A (Trial 1 and 2): Determining the Minimally Effective Dose of Sucrose for Procedural Pain in Infants
Brief Summary: Recent studies show that babies in hospital undergo an average of 4 to 5 painful procedures, such as heel lances, every day. Sucrose (sugar water) has been shown to be effective for reducing pain during invasive procedures and is a standard of care for painful procedures. The purpose of this study is to see what is the least amount of sucrose that can be given to a baby to reduce pain during procedures.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: 25% Sucrose | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: facilitated tucking | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Sucrose and facilitated tucking | Intervention Type: PROCEDURE; Name: 25% Sucrose; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: facilitated tucking; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Sucrose and facilitated tucking; Assigned to Arm(s): 3
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Other: N2O | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: oxygen | Intervention Type: OTHER; Name: N2O; Assigned to Arm(s): A | Intervention Type: OTHER; Name: oxygen; Assigned to Arm(s): B
C: Arm Label: 0.1ml 24% sucrose concurrent opioids; Type: ACTIVE_COMPARATOR; Interventions: Other: sucrose | Arm Label: 0.5ml 24% sucrose concurrent opioids; Type: ACTIVE_COMPARATOR; Interventions: Other: sucrose | Arm Label: 1.0ml 24% sucrose concurrent opioids; Type: ACTIVE_COMPARATOR; Interventions: Other: sucrose | Arm Label: 0.1ml 24% sucrose no opioids; Type: ACTIVE_COMPARATOR; Interventions: Other: sucrose | Arm Label: 0.5ml 24% sucrose no opioids; Type: ACTIVE_COMPARATOR; Interventions: Other: sucrose | Arm Label: 1.0ml 24% sucrose no opioids; Type: ACTIVE_COMPARATOR; Interventions: Other: sucrose | Intervention Type: OTHER; Name: sucrose; Assigned to Arm(s): 0.1ml 24% sucrose concurrent opioids, 0.1ml 24% sucrose no opioids, 0.5ml 24% sucrose concurrent opioids, 0.5ml 24% sucrose no opioids, 1.0ml 24% sucrose concurrent opioids, 1.0ml 24% sucrose no opioids
D: Arm Label: Breastfeeding; Type: EXPERIMENTAL; Interventions: Other: Breastfeeding | Arm Label: 24% oral sucrose; Type: ACTIVE_COMPARATOR; Interventions: Drug: 24% oral sucrose | Intervention Type: OTHER; Name: Breastfeeding; Assigned to Arm(s): Breastfeeding | Intervention Type: DRUG; Name: 24% oral sucrose; Assigned to Arm(s): 24% oral sucrose

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sucrose Practices for Pain in Neonates: A Program of Research: Part A (Trial 1 and 2): Determining the Minimally Effective Dose of Sucrose for Procedural Pain in Infants
Brief Summary: Recent studies show that babies in hospital undergo an average of 4 to 5 painful procedures, such as heel lances, every day. Sucrose (sugar water) has been shown to be effective for reducing pain during invasive procedures and is a standard of care for painful procedures. The purpose of this study is to see what is the least amount of sucrose that can be given to a baby to reduce pain during procedures.


Options:
A: N/A
B: Arm Label: Group 1; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Educational Video - Sham, Drug: Sucrose Placebo (water), Drug: Lidocaine Placebo | Arm Label: Group 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational video - Active, Drug: Sucrose Placebo (water), Drug: Lidocaine Placebo | Arm Label: Group 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational video - Active, Drug: Sucrose, Drug: Lidocaine Placebo | Arm Label: Group 4; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational video - Active, Drug: Sucrose, Drug: Lidocaine | Intervention Type: BEHAVIORAL; Name: Educational video - Active; Assigned to Arm(s): Group 2, Group 3, Group 4 | Intervention Type: BEHAVIORAL; Name: Educational Video - Sham; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Sucrose Placebo (water); Assigned to Arm(s): Group 1, Group 2 | Intervention Type: DRUG; Name: Sucrose; Assigned to Arm(s): Group 3, Group 4 | Intervention Type: DRUG; Name: Lidocaine Placebo; Assigned to Arm(s): Group 1, Group 2, Group 3 | Intervention Type: DRUG; Name: Lidocaine; Assigned to Arm(s): Group 4
C: Arm Label: 0.1ml 24% sucrose concurrent opioids; Type: ACTIVE_COMPARATOR; Interventions: Other: sucrose | Arm Label: 0.5ml 24% sucrose concurrent opioids; Type: ACTIVE_COMPARATOR; Interventions: Other: sucrose | Arm Label: 1.0ml 24% sucrose concurrent opioids; Type: ACTIVE_COMPARATOR; Interventions: Other: sucrose | Arm Label: 0.1ml 24% sucrose no opioids; Type: ACTIVE_COMPARATOR; Interventions: Other: sucrose | Arm Label: 0.5ml 24% sucrose no opioids; Type: ACTIVE_COMPARATOR; Interventions: Other: sucrose | Arm Label: 1.0ml 24% sucrose no opioids; Type: ACTIVE_COMPARATOR; Interventions: Other: sucrose | Intervention Type: OTHER; Name: sucrose; Assigned to Arm(s): 0.1ml 24% sucrose concurrent opioids, 0.1ml 24% sucrose no opioids, 0.5ml 24% sucrose concurrent opioids, 0.5ml 24% sucrose no opioids, 1.0ml 24% sucrose concurrent opioids, 1.0ml 24% sucrose no opioids
D: Arm Label: OH; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Hernia repair | Arm Label: LH; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Hernia repair | Intervention Type: PROCEDURE; Name: Hernia repair; Assigned to Arm(s): LH, OH

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Double-blind, Double-dummy, Randomized, Placebo And Active Controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Dyslipidemia Who Are Intolerant To Statins
Brief Summary: This study is a multicenter, double blinded, active and placebo controlled randomized clinical trial to demonstrate a superior lipid lowering effect of Bococizumab (PF-04950615; RN316) compared to placebo in subjects who are statin intolerant.


Options:
A: Arm Label: Bococizumab (PF-04950615; RN316); Type: EXPERIMENTAL; Interventions: Drug: Bococizumab (PF-04950615; RN316) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Bococizumab (PF-04950615; RN316); Assigned to Arm(s): Bococizumab (PF-04950615; RN316) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Standard of Care; Type: ACTIVE_COMPARATOR; Interventions: Biological: Evolocumab, Other: Standard of care | Arm Label: Evolocumab + SOC; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab | Intervention Type: BIOLOGICAL; Name: Evolocumab; Assigned to Arm(s): Evolocumab + SOC, Standard of Care | Intervention Type: OTHER; Name: Standard of care; Assigned to Arm(s): Standard of Care
C: Arm Label: Placebo Q2W; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for alirocumab), Drug: Lipid Modifying Therapy (LMT) | Arm Label: Alirocumab 150 mg Q2W; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Lipid Modifying Therapy (LMT) | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 150 mg Q2W | Intervention Type: DRUG; Name: Placebo (for alirocumab); Assigned to Arm(s): Placebo Q2W | Intervention Type: DRUG; Name: Lipid Modifying Therapy (LMT); Assigned to Arm(s): Alirocumab 150 mg Q2W, Placebo Q2W
D: Arm Label: Bococizumab (PF-04950615;RN316); Type: EXPERIMENTAL; Interventions: Drug: Bococizumab (PF-04950615;RN316) | Arm Label: Atorvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo for Bococizumab (PF-04950615;RN316), Other: Placebo for atorvastatin | Intervention Type: DRUG; Name: Bococizumab (PF-04950615;RN316); Assigned to Arm(s): Bococizumab (PF-04950615;RN316) | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin | Intervention Type: OTHER; Name: Placebo for Bococizumab (PF-04950615;RN316); Assigned to Arm(s): Placebo | Intervention Type: OTHER; Name: Placebo for atorvastatin; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Does Breaking Sedentary Time Improve Glucose Regulation in Women With Impaired Glucose Tolerance? A Balanced Incomplete Block Design Study
Brief Summary: The number of people diagnosed with Type 2 diabetes (T2DM) is increasing rapidly and about 2.9 million people in the UK currently have diabetes. There is increasing evidence suggesting that prolonged sedentary time may actually increase the risk of diabetes and other chronic diseases. Importantly, adults can meet public health guidelines on physical activity (150 minutes of moderate activity per week), but if they still sit for prolonged periods, their metabolic health is compromised. Going from sitting to standing and carrying out light-intensity activities (such as casual walking) may reduce diabetes risk. However, no one has investigated the effect of standing and walking on markers of cardio-metabolic markers in individuals with a high risk of T2DM. Therefore, the aim is to find out whether reducing the amount of time people spend sitting and replacing it with standing and light intensity activity (walking) reduces glucose, insulin and triglyceride levels, therefore reducing the risk of diabetes.


Options:
A: Arm Label: m-health stroke rehabilitation; Type: N/A; Interventions: Behavioral: Multimodal Exercise Rehabilitation Program | Intervention Type: BEHAVIORAL; Name: Multimodal Exercise Rehabilitation Program; Assigned to Arm(s): m-health stroke rehabilitation
B: Arm Label: Virtual Reality Therapy; Type: EXPERIMENTAL; Interventions: Other: Virtual Reality | Arm Label: Traditional Therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Traditional Therapy | Intervention Type: OTHER; Name: Virtual Reality; Assigned to Arm(s): Virtual Reality Therapy | Intervention Type: OTHER; Name: Traditional Therapy; Assigned to Arm(s): Traditional Therapy
C: Arm Label: Rehabilitation training; Type: EXPERIMENTAL; Interventions: Other: Rehabilitation | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Rehabilitation; Assigned to Arm(s): Rehabilitation training
D: Arm Label: Sitting; Type: EXPERIMENTAL; Interventions: Behavioral: Sitting | Arm Label: Standing; Type: EXPERIMENTAL; Interventions: Behavioral: Standing | Arm Label: Walking; Type: EXPERIMENTAL; Interventions: Behavioral: Walking | Intervention Type: BEHAVIORAL; Name: Sitting; Assigned to Arm(s): Sitting | Intervention Type: BEHAVIORAL; Name: Standing; Assigned to Arm(s): Standing | Intervention Type: BEHAVIORAL; Name: Walking; Assigned to Arm(s): Walking

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Belgian Trial With Azithromycin During Acute COPD Exacerbations
Brief Summary: This project (funded by the IWT-TBM program) will organize a randomized placebo-controlled multicenter intervention trial in 500 COPD patients to study the effectiveness and safety of azithromycin therapy in the acute setting of COPD exacerbations requiring hospital admission. Although long-term use of azithromycin is proven effective to prevent exacerbations, inherent risks outweigh the benefits. By reducing the dose and duration of the azithromycin treatment and by restricting the treatment to acute periods with highest risk for treatment failure, benefits may counterbalance potential side effects, which may result in a new treatment strategy for these acute events.

The present study is designed by the services of respiratory medicine of the Leuven and Ghent University hospitals but will run in total in 17 different large hospitals in Belgium, of which 12 are located in Flanders.


Options:
A: Intervention Type: DRUG; Name: Erythromycin; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
C: Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Arm I; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Carboplatin | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Drug: Gemcitabine Hydrochloride | Arm Label: Arm III; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Drug: Pegylated Liposomal Doxorubicin Hydrochloride | Arm Label: Arm IV; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Drug: Topotecan Hydrochloride | Arm Label: Arm V; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Drug: Gemcitabine Hydrochloride, Procedure: Therapeutic Conventional Surgery | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I, Arm II, Arm III, Arm IV, Arm V | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm I, Arm II, Arm III, Arm IV, Arm V | Intervention Type: DRUG; Name: Gemcitabine Hydrochloride; Assigned to Arm(s): Arm II, Arm V | Intervention Type: DRUG; Name: Pegylated Liposomal Doxorubicin Hydrochloride; Assigned to Arm(s): Arm III | Intervention Type: DRUG; Name: Topotecan Hydrochloride; Assigned to Arm(s): Arm IV | Intervention Type: PROCEDURE; Name: Therapeutic Conventional Surgery; Assigned to Arm(s): Arm V

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Belgian Trial With Azithromycin During Acute COPD Exacerbations
Brief Summary: This project (funded by the IWT-TBM program) will organize a randomized placebo-controlled multicenter intervention trial in 500 COPD patients to study the effectiveness and safety of azithromycin therapy in the acute setting of COPD exacerbations requiring hospital admission. Although long-term use of azithromycin is proven effective to prevent exacerbations, inherent risks outweigh the benefits. By reducing the dose and duration of the azithromycin treatment and by restricting the treatment to acute periods with highest risk for treatment failure, benefits may counterbalance potential side effects, which may result in a new treatment strategy for these acute events.

The present study is designed by the services of respiratory medicine of the Leuven and Ghent University hospitals but will run in total in 17 different large hospitals in Belgium, of which 12 are located in Flanders.


Options:
A: Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: azithromycin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: azithromycin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
C: Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: azithromycin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: azithromycin; Assigned to Arm(s): azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo

Answer: A